Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor

Multiple Cancer Types

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study is a global, open-label Phase 2 study to determine the efficacy and safety of KRT-232 in patients with primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF who have failed previous treatment with JAK inhibitor (Part A), or Ruxolitinib (Part B). In Part A of the study, patients will be randomly assigned to 2 different doses and 3 different dosing schedules of KRT-232. In Part B of the study, patients will be treated at the recommended dose and schedule from Part A.
Hematologic, Leukemia
II
Mohan, Sanjay
NCT03662126
VICCHEM18136

Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile, maximum tolerable dose (MTD) and cohort expansion of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
I
Mohan, Sanjay
NCT03309111
VICCHEMP17111

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed / Refractory Acute Myeloid Leukemia (AML)

Multiple Cancer Types

To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed / refractory (R / R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.
Leukemia, Phase I
I
Mohan, Sanjay
NCT04155580
VICCHEMP19144

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: